Recruiting

Testing ongoing immune therapy after head and neck cancer treatment

Plain-English translation of NCT06208826 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a medication called as an ongoing immune therapy for people with advanced head and neck squamous cell carcinoma who have already responded well to an initial combination of immune therapy and chemotherapy followed by surgery. The goal is to see whether continuing this immune therapy helps prevent the cancer from coming back and improves long-term survival. Researchers believe that maintaining this immune treatment after achieving a strong initial response could give patients a better chance of staying cancer-free.

Head and neck cancer is a serious disease, and even with standard treatment, survival rates remain low—less than 30% at five years for advanced cases. Early evidence suggests that continuing immune therapy after surgery may be safer and more effective than traditional approaches alone, which is why researchers want to study this maintenance strategy in patients who have already shown a strong response to their initial treatment.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with advanced head and neck squamous cell carcinoma that has not spread to distant sites
you have already completed initial immune therapy combined with chemotherapy and surgery, and your cancer showed a major response
you are in good enough overall health to tolerate additional treatment, with normal or near-normal blood counts, liver, and kidney function
you are able to understand the study and willing to provide informed consent

You likely don't qualify if…

you have cancer that has spread to other parts of your body or cannot be surgically removed
you have an active autoimmune disease or a serious history of autoimmune problems requiring ongoing treatment
you have active hepatitis B or C, HIV, or a weakened immune system
you have or have had serious lung problems, including certain types of pneumonia or active tuberculosis
you are currently taking part in another clinical trial or have taken an investigational drug in the past 4 weeks

What participation looks like

If you qualify, you would receive the medication by intravenous infusion every three weeks for about 15 cycles (roughly nine to twelve months of treatment). You will have regular clinic visits to receive each infusion and to check your health through blood tests and imaging scans. The research team will monitor you closely for side effects and signs of how well the treatment is working to keep your cancer from returning.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Testing ongoing immune therapy after head and neck cancer treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)